SciELO - Scientific Electronic Library Online

 
vol.30 número2Morbidity and mortality maternal health in an institution 2012The science concept as a system, positivism, neopositivism and "quantitative and qualitative research índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Em processo de indexaçãoCitado por Google
  • Não possue artigos similaresSimilares em SciELO
  • Em processo de indexaçãoSimilares em Google

Compartilhar


Revista Salud Uninorte

versão On-line ISSN 2011-7531

Resumo

ROMERO PRADA, Martín; ALVIS GUZMAN, Nelson; CHAVEZ BEJARANO, Diana  e  KARPF BENAVIDES, Elizabeth. Cost-effectiveness of using Detemir for patients with type 2 diabetes in risk of cardiovascular events and death in Colombia. Salud, Barranquilla [online]. 2014, vol.30, n.2, pp.200-209. ISSN 2011-7531.

Objective: Analyze the cost-effectiveness of using Detemir versus using other insulins (Glargine and NPH insulin) for treatment of type 2 diabetes in Colombia. Methods: A Markov model was used to evaluate cost-effectiveness of Determir from a third-party payer's perspective in a hypothetical cohort of 10,000 patients, aged 45 years, with type 2 diabetes in risk of cardiovascular events and death in a 5-year time horizon. Both cardiovascular events and deaths avoided -expressed in Life-Year Saved- related to severe hypoglycemia events were considered as outcomes. Costs were obtained from health care providers databases at 2013 prices. A discount rate of 3% was applied to costs and outcomes. A sensitivity analysis was conducted to test the robustness of the model. Results: In the model, using Detemir has fewer numbers of severe hypoglycemic events (730) versus NPH insulin (1,910) and Glargine (2,140), and fewer number of macrovas-cular (1,053) and microvascular (1,019) events versus Glargine (1,116; 1,037) and NPH (1,129; 1,042). Using Detemir, 122 and 147 deaths were avoided compared to Glargine and NPH respectively; those figures are respectively equivalent to 4,233and 3,513 Life-Year Saved. As discount was applied the ICER per Life-Year Saved for Detemir versus Glargine was US$ 998.39 and USD 4,096.86 against NPHinsulin. In the Montecarlo sen-sitivity analysis Detemir remains cost effective in 100% of cases according to the WHO-proposed threshold. Conclusion: From a third-party payer's perspective,Detemir is cost-effective compared to Glargine and NPH insulin for treatment of type 2 diabetes in Colombia.

Palavras-chave : type 2 diabetes; Detemir; insulin; insulin Glargine; cost-effectiveness.

        · resumo em Espanhol     · texto em Espanhol     · Espanhol ( pdf )